A study of comparative effects of Antioxidants on Insulin Sensitivity in type 2 diabetes mellitus: A Randomized Double Blinded Placebo-Controlled Trial

MERCK India Ltd0 sites0 target enrollmentStarted: TBDLast updated: November 24, 2021

Overview

No summary available.

•This study will enrol patients both men and women with age between 21\-60 years of known cases of type 2 diabetes mellitus, attending medicine or diabetic O.P.D of SGH Pune and having the following parameters \-indicative of decreased insulin sensitivity:\-
•Any of the below two criteria:
•1\)B.M.I \> 27 kg/m2 \- \< 40 kg/m2 17
•2\)Waist circumference of \> 102 cm in men or \> 88 cm in women
•3\)High\-density lipoprotein cholesterol (HDL\-C) level of \< 40 mg/dL in men or \< 50 mg/dL in women/ Fasting triglyceride level of 150 mg/dL or higher

•1\)Patient with type 2 diabetes mellitus with blood glucose \> 250 mg/dL or patients who are currently on insulin therapy17
•2\)Patients with uncontrolled hypertension ( Blood pressure \> 140/90mmHg in spite of anti HT drugs)
•3\) Patients with complications of diabetes including nephropathy \& retinopathy17
•4\)Patients with serum levels of triglycerides \>400 mg/dL17/ Patients with total cholesterol \> 400 mg/dL17
•5\)Any history of MI/cardiac intervention or clinically active cardiovascular disease17
•6\)Patients with known renal or hepatic diseases ( AST \> 82 U/L; ALT \> 76 U/L; Creatinine \> 1\.5mg/dL) 17 including any history of renal stones
•7\)Pregnant females will be excluded
•8\)Patients taking any long term medication except anti\-diabetic, antilipedimic and antihypertensive medicines.
•9\)Unwillingness to give blood samples or mental incapacity to take the drugs

Sponsor

MERCK India Ltd